FABERCO TURNS OVER MOLNUPIRAVIR, THE FIRST-EVER COVID-19 ORAL TREATMENT TO THE CITY OF MANILA

Faberco Life Sciences, Inc. turn over today, November 23, 2021, the first batch of MOLNUPIRAVIR (Molnarz™) to the City of Manila in a ceremony held at the Manila COVID-19 Field Hospital in Luneta.

Received by Manila Mayor Isko Moreno, Vice Mayor Honey Lacuna, and Doc Willie Ong, the City of Manila is the first Local Government Unit to procure MOLNUPIRAVIR (Molnarz™) through Faberco Life Sciences, Inc. The Santa Ana Hospital through Compassionate Special Permit (CSP) issued by the Philippine Food and Drug Administration is the recipient / receiving hospital for this batch of allotment for Manila LGU.

Molnupiravir is the first oral antiviral drug that will prevent mild to moderate cases of COVID-19 from progressing into severe disease that needs hospitalization. It is taken as a pill rather than given as an injection.

Though not yet available commercially, Faberco Life Sciences, Inc. together with RiteMED, distributes MOLNUPIRAVIR (Molnarz™) to hospitals, medical institutions, and treatment sites under compassionate use which allow institutions to procure and distribute products under study, or those awaiting approval for immediate use in emergency situations.

ABOUT FABERCO LIFE SCIENCES, INC.

Faberco Life Sciences Inc. (FLS), a Philippine biopharmaceutical organization, is focused on providing innovative, highly niche pharmaceutical products to both public and private health sectors. Faberco partners with reputable international manufacturers who target product platforms and therapeutic categories to treat and prevent diseases which are of public health concern.

For Inquiries:
Neil M. Maristela
Head of Public Relations
M: 09272344489
E: neil@faberco.ph